Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given
prior to an autologous stem cell transplant and to see how well they work in treating
patients with multiple myeloma. Drugs used in chemotherapy, such as melphalan, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Bortezomib may help melphalan work
better by making cancer cells more sensitive to the drug. Giving chemotherapy before an
autologous hematopoietic stem cell transplant helps kill any cancer cells that are in the
body and helps make room in the patient's bone marrow for new blood-forming cells (stem
cells) to grow. After treatment, stem cells are collected from the patient's blood and
stored. More chemotherapy is then given to prepare the bone marrow for the stem cell
transplant. The stem cells are then returned to the patient to replace the blood-forming
cells that were destroyed by the chemotherapy. Giving melphalan together with bortezomib
prior to autologous hematopoietic stem cell transplant may be a better treatment for multiple
myeloma.